TRVI Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 5.21%, SMA50 1.5%, SMA200 24.76%). The stock’s 14-day RSI is 56.77 (neutral), while the ATR of 0.64 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.94% below its high and over 176.26% above its low. Average 10-day trading volume of 2.88 million shares is slightly above the 3-month average of 2.04 million, indicating heightened recent market interest.

Trevi Therapeutics, Inc. has 121.78 million shares outstanding. The public float is 90.63 million shares, elevated short interest at 11.12% of float. This equals 11.68 million shares. The short ratio is 6.36 days. Institutional investors hold 98.88% of the float. Insiders own 0.63%. New Enterprise Associates 16, L.P. holds 10.42 million shares, NEA 16 GP, LLC has 10.42 million shares and BASKETT FOREST has 10.42 million shares.

Trevi Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.13. This means the shares are trading above this model’s fair value.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) closed at $16.52 USD, losing -$1.32 (-7.40%) from the previous close of $17.84. The stock is currently mid-range between its 52-week high and low $6.50 and $20.15. With a market capitalization of about $2.35 billion, Trevi Therapeutics, Inc. is classified as a mid-cap and shows market-like volatility (beta ~1.00). Key stats such as the average daily volume over the past year has been around 1.95 million shares, in line with its 52-week average. Headquartered in New Haven, CT, Trevi Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jennifer L. Good, the company employs approximately 34 people and listed since May 07, 2019. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the advancement and commercialization of Haduvio, a potential treatment for debilitating neurologically mediated conditions.

Trevi Therapeutics, Inc. generated EPS of -$0.37 over the past year. Five-year average earnings growth is 27.09%. Wall Street analysts project EPS growth of -9.46% annually over the next five years. The latest quarter delivered EPS of -$0.09. The next quarter is forecast at -$0.10. Next year's EPS is expected at -$33.15. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 15 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $27.00 to $16.00. The high target offers 63.44% upside. The low target suggests -3.15% downside. The mean target is $20.71. This offers 25.36% upside. Trevi Therapeutics, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 05, 2026, missed forecasts by 28.57%. The prior quarter beat by -40.0%. Over the last six quarters, Apple has recorded several small beats. These include -8.33% in March 18, 2025.

Our AI price prediction model suggests that Trevi Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 18.1%, with price expected at $19.51 by July 27, 2026, within a range of $18.53 to $20.46 3-Month Outlook: Projected rise of 70.88%, reaching $28.23 by October 08, 2026, with a range of $27.76 to $28.79. 1-Year Outlook: Projected gain of 31.9%, with price at $21.79 by July 13, 2027, within a range of $20.92 to $22.55.

Trevi Therapeutics, Inc. (NASDAQ:TRVI) shares are down -16.77% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Trevi Therapeutics, Inc. trading at a premium to the broader market with a P/E of -51.77. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.09, suggesting 3.45% upside. Our AI forecast model points to short-term strength (18.1% over two weeks), a medium-term rise (70.88% over three months), and a longer-term gain (31.9% over one year), with expected trading ranges indicating moderate volatility.

Trevi Therapeutics, Inc. trades at a P/E ratio of -51.77, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 14.11 reflecting a rich premium to book value. The P/FCF stands at -74.15, also below market averages. Compared to sector medians, Trevi Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.